Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan

被引：22

作者：

O'Reilly, S ^{[1
]}

Armstrong, DK ^{[1
]}

Grochow, LB ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA

来源：

GYNECOLOGIC ONCOLOGY | 1997年 / 67卷 / 03期

关键词：

D O I：

10.1006/gyno.1997.4896

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：329 / 330

页数：2

共 4 条

[1] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].

COCKCROFT, DW ;

GAULT, MH .

NEPHRON, 1976, 16 (01) :31-41

[2] Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J].

Huinink, WTB ;

Gore, M ;

Carmichael, J ;

Gordon, A ;

Malfetano, J ;

Hudson, I ;

Broom, C ;

Scarabelli, C ;

Davidson, N ;

Spanczynski, M ;

Bolis, G ;

Malmstrom, H ;

Coleman, R ;

Fields, SC ;

Heron, JF .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2183-2193

[3]

JELIFFE RW, 1973, ANN INTERN MED, V79, P604

[4] Phase I and pharmacologic study of topotecan in patients with impaired renal function [J].

OReilly, S ;

Rowinsky, EK ;

Slichenmyer, W ;

Donehower, RC ;

Forastiere, AA ;

Ettinger, DS ;

Chen, TL ;

Sartorius, S ;

Grochow, LB .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) :3062-3073

← 1 →